Law360 (February 14, 2018, 2:13 PM EST) -- Nektar Therapeutics has inked a $1.85 billion cash-and-stock deal to jointly develop and manage its cancer-fighting, immuno-stimulatory therapy in combination with two Bristol-Myers Squibb …
This morning the Bay Area-based company forged a new collaboration with pharma giant Bristol-Myers Squibb to develop and commercialize ... the acquisition of more than 8 million shares of common stock. Additionally, Nektar will be …
What was the reason Bristol-Myers Squibb Co (NYSE:BMY) sold off Monday? Was it based on the company’s earnings report or did BMY stock take a fall thanks to the overall market? After all, the SPDR S&P 500 ETF Trust …
On the one hand, fundamentally BMY is not expensive relative to its peers from a price-to-earnings perspective. It also has a decent balance sheet and runs respectable net margins so there aren’t any obvious issues. But on the other hand, …
Shares of Bristol-Myers Squibb Co. (ticker: BMY) fell more than 16 percent Friday after the company announced that its Opdivo drug failed a study that would have expanded its use to lung cancer patients. BMY stock dropped more than …
Bristol-Myers Squibb's stock fell nearly 10 percent yesterday after the company released a disappointing earnings forecast. The news helped send the prices of other drug stocks tumbling. . The shares of the Bristol-Myers Squibb …
Bristol-Myers Squibb (NYSE: BMY), in many ways, has led the immuno-oncology revolution with its game-changing checkpoint inhibitors Opdivo and Yervoy. However, the stock has lost a bit of its shine in the past year, thanks to …
In this series, we look through the most recent Dividend Channel ''DividendRank'' report, and then we cherry pick only those companies that have experienced insider buying within the past six months. The officers and directors of a company …
NASDAQ4mon
Shares of Bristol-Myers Squibb Company (BMY) have risen almost 11% in the past 30 days, fueled by optimism that President-elect Donald Trump would lessen the shackles of regulation that force drug companies to keep prices low. …
Bristol-Myers Squibb Co (NYSE:BMY) stock has had a tumultuous 12-month period. In January, it fell 20% but luckily for the bulls it recovered all of it within five weeks. Since then and after several +/-8% moves, BMY is up 12% in 52 weeks …